全国同城凤凰楼信息茶楼_51pcmc品茶2024官网_全国兼职凤凰楼信息

Biography

Dr.Yin obtained his bachelor’s degree in 2011 from Soochow University in China. He then went to Shanghai Institute of Materia Media, Chinese Academy of Sciences, where he earned his Ph.D. in drug design in 2017. He worked for 3 years at the Center for Structure & Function of Drug Targets, Shanghai Institute of Materia Media, Chinese Academy of Sciences, following a postdoctoral Fellowship. In 2020, he was promoted to research associate and again to associate professor in October. In January 2022, he became a Senior Investigator and joined ZIDD as a principal investigator.

Research Directions

1. Research on the structure and function of drug targets related to viral infectious diseases;

2. Study at the structure and function of key membrane protein complexes;

3. Structure-based new drug design and development.

Achievements

Dr.Yin has published more than 20 scientific papers, which have been cited over 1500 times. One paper was recommended by the Faculty of 1000 for comments, and was selected as the ESI Highly Cited Paper (Top 1%). The cryo electron microscopy (cryo-EM) structure of SARS-CoV-2 RdRp complex bound to the RNA and nucleotide drug remdesivir was chosen as the September Molecule of the Month in September 2020 by the Protein Data Bank (PDB). He presided over and participated in a number of scientific research projects, including the Youth Innovation Promotion Association of the Chinese Academy of Sciences, the Outstanding Youth Fund of the National Natural Science Foundation of China. He was awarded the nomination award of Shanghai's "Most Beautiful Retired Soldier", Sanofi "2021 Young Faculty Award", Outstanding young scientific and technological workers of Shanghai Institute of Materia Media, Chinese Academy of Sciences and other honors.

1. He resolved the structural basis of serotonin receptors regulated by inverse agonists in the doctoral period. And the research has resulted in an interesting publication in Cell Discovery, in which he was the sole first author.

2. He finally solved a complex structure of beta-arrestin bound to a non-visual GPCR, which reveals a unique binding mode distinct from that of the visual arrestin-GPCR complex. Sequence alignment and homology modeling suggest that the structure is representative for many GPCRs and provides a general paradigm for modeling β-arrestin–GPCR interactions. This truly is a major milestone in the field of GPCR research, which will have a lasting impact on our understanding of GPCR biased signaling and biased ligand design.

3. Since the outbreak of the COVID-19 pandemic in the early 2020, together with his team to fight with the SARS-CoV-2, he successfully solved the structures of SARS-CoV-2 RdRp complex bound to the RNA and nucleotide drug remdesivir, and non-nucleotide drug suramin respectively, which would promote the development of antiviral drugs targeting RdRp against COVID-19. This achievement was selected as the major scientific and technological achievement of the first phase of the "first action plan" of the Chinese Academy of Sciences in 2020. In addition, they reported a series of high-resolution cryo-EM structures of the Omicron Spike trimer with human and mouse ACE2, and an anti-Omicron antibody JMB2002. These timely reports revealed the basis for Omicron higher infectivity, immune evasion, and antibody drug discovery, and suggested a possible evolution pathway for Omicron BA.1 and BA.2 variants from human-cat-mouse-human circle, which could have important implications in the development of effective therapies for viral infection.

4. Besides, he has participated in the development of several new drugs, including the DC20, which is an anti-AD candidate drug and has been approved to enter the phase II clinical study, and VV116, an oral nucleoside anti-COVID-19 drug, which has been authorized for emergency use in some countries and regions.

Publications

1.Changyao Li, Youwei Xu, Heng Liu, Hongmin Cai, Yi Jiang, H. Eric Xu^* & Wanchao Yin ^*. Molecular recognition of itch-associated neuropeptides by bombesin receptors. Cell Research（2022）；0:1–4.

2.Youwei Xu^#, Canrong Wu^#, Xiaodan Cao^#, Chunyin Gu^#, Heng Liu^#, Mengting Jiang, Xiaoxi Wang, Qingning Yuan, Kai Wu, Jia Liu, Deyi Wang, Xianqing He, Xueping Wang, Su-Jun Deng^*, H. Eric Xu^*, Wanchao Yin^*. Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.1 and BA.2 variants and their possible mouse origins. Cell Research（2022）;0:1–12.

3. Wanchao Yin^*#, Youwei Xu^#, Peiyu Xu^#, Xiaodan Cao^#, Canrong Wu^#, Chunyin Gu^#, Xinheng He, Xiaoxi Wang, Sijie Huang, Qingning Yuan, Kai Wu, Wen Hu, Zifu Huang, Jia Liu, Zongda Wang, Fangfang Jia, Kaiwen Xia, Peipei Liu, Xueping Wang, Bin Song, Jie Zheng, Hualiang Jiang, Xi Cheng, Yi Jiang, Su-Jun Deng^*, H. Eric Xu^* . Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody. Science (2022); 375(6584): 1048-1053.

4. Wenjing Sun ^#, Qingning Yuan ^#, Huanhuan Zhang ^#, Fan Yang, Shenglong Ling, Yifan Luo, Pei Lv, H Eric Xu*, Changlin Tian^*, Wanchao Yin^*, and Pan Shi^*. Structural insights into the activation of neurokinin 2 receptor by neurokinin A. Cell Discovery (2022); 8(1):72.

5. Wanchao Yin^#, Chunyou Mao^#, Xiaodong Luan^#, Dan-Dan Shen^#, Qingya Shen^#, Haixia Su^#, Xiaoxi Wang, Fulai Zhou, Wenfeng Zhao, Minqi Gao, Shenghai Chang, Yuan-Chao Xie, Guanghui Tian, He-Wei Jiang, Sheng-Ce Tao, Jingshan Shen, Yi Jiang, Hualiang Jiang, Yechun Xu^*, Shuyang Zhang^*, Yan Zhang^*, H. Eric Xu^*. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science（2020）; 368(6498): 1499-1504.

6. Wanchao Yin^#, Zhihai Li^#, Mingliang Jin^#, Yu-Ling Yin^#, Parker W. de Waal, Kuntal Pal, Yanting Yin, Xiang Gao, Yuanzheng He, Jing Gao, Xiaoxi Wang, Yan Zhang, Hu Zhou, Karsten Melcher, Yi Jiang, Yao Cong^*, X. Edward Zhou^*, Xuekui Yu^* and H. Eric Xu^*. A complex structure of arrestin-2 bound to a G protein-coupled receptor. Cell Research（2019）; 29(12):971–983.

7. Wanchao Yin^#, Xiaodong Luan^#, Zhihai Li^#, Ziwei Zhou^#, Qingxing Wang^#, Minqi Gao, Xiaoxi Wang, Fulai Zhou, Jingjing Shi, Erli You, Mingliang Liu, Qingxia Wang, Yi Jiang, Hualiang Jiang, Gengfu Xiao, Leike Zhang^*, Xuekui Yu^*, Shuyang Zhang^*, H. Eric Xu^*. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nature Structural & Molecular Biology （2021）；28(3): 319-325.

8. Yuanchao Xie^#, Wanchao Yin^#, Yumin Zhang^#, Weijuan Shang, Zhen Wang, Xiaodong Luan, Guanghui Tian, Haji A Aisa, Yechun Xu, Gengfu Xiao, Jia Li, Hualiang Jiang, Shuyang Zhang, Leike Zhang^*, H Eric Xu^*, Jingshan Shen^*.  (2021). "Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2". Cell Research（2021）; 31(11): 1212-1214.

9. Yu-Ling Yin^#, Chenyu Ye^#, Fulai Zhou, Jia Wang, Dehua Yang, Wanchao Yin^*, Ming-Wei Wang^*, H. Eric Xu^*, Yi Jiang^*. (2021). " Molecular basis for kinin selectivity and activation of the human bradykinin receptors " .Nature Structural & Molecular Biology（2021）； 28(9): 755-761.

10. Yu Zhou^#, Yan Fu^#, Wanchao Yin^#, Jian Li, Wei Wang, Fang Bai, Shengtao Xu, Qi Gong, Tao Peng, Yu Hong, Dong Zhang, Dan Zhang, Qiufeng Liu, Yechun Xu, H Eric Xu, Haiyan Zhang^*, Hualiang Jiang^* and Hong Liu^*. Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate. J Med Chem（2021）;64(4):1844-1855.

11. Peng-xuan Ren^#, Wei-juan Shang^#, Wanchao Yin^#, Huan Ge, Lin Wang, Xiang-lei Zhang, Bing-qian Li, Hong-lin Li, Ye-chun Xu, Eric H. Xu, Hua-liang Jiang, Li-li Zhu^*, Lei-ke Zhang^* & Fang Bai^*. "A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors." Acta Pharmacol Sin (2021); 43(2):483-493.

12. Wanchao Yin, X. Edward Zhou, Dehua Yang, Parker W. de Waal, Meitian Wang, Antao Dai, Xiaoqing Cai, Chia-Ying Huang, Ping Liu, Xiaoxi Wang, Yanting Yin, Bo Liu, Yu Zhou, Jiang Wang, Hong Liu, Martin Caffrey, Karsten Melcher, Yechun Xu, Ming-Wei Wang^*, H. Eric Xu^* and Yi Jiang^*. Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist. Cell discovery. (2018); 4:12.

13. Yi Jiang^*, WanchaoYin, H. Eric Xu^*. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. Biochem Biophys Res Commun (2021); 538:47-53.

14. Fulai Zhou^#, Chenyu Ye^#, Xiaomin Ma^#, Wanchao Yin, Tristan I Croll, Qingtong Zhou, Xinheng He, Xiaokang Zhang, Dehua Yang, Peiyi Wang^*, H Eric Xu^*, Ming-Wei Wang^*, Yi Jiang^*. Molecular basis of ligand recognition and activation of human V2 vasopressin receptor. Cell Research (2021); 31(8): 929-931.

15. Fenghui Zhao, Chao Zhang, Qingtong Zhou, Kaini Hang, Xinyu Zou, Yan Chen, Fan Wu, Qidi Rao, Antao Dai, Wanchao Yin, Dan-Dan Shen, Yan Zhang, Tian Xia, Raymond C Stevens, H Eric Xu, Dehua Yang, Lihua Zhao, Ming-Wei Wang. Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor. Elife (2021); 10:e68719.

16. Jia Duan^#, Peiyu Xu^#, Xi Cheng^#, Chunyou Mao^#, Tristan Croll, Xinheng He, Jingjing Shi, Xiaodong Luan, Wanchao Yin, Erli You, Qiufeng Liu, Shuyang Zhang, Hualiang Jiang, Yan Zhang^*, Yi Jiang^*, H Eric Xu^*. Structures of full-length glycoprotein hormone receptor signalling complexes. Nature (2021); 598(7882): 688-692.

17. Qiufeng Liu^#, Dehua Yang^#, Youwen Zhuang^#, Tristan I Croll, Xiaoqing Cai, Antao Dai, Xinheng He, Jia Duan, Wanchao Yin, Chenyu Ye, Fulai Zhou, Beili Wu, Qiang Zhao, H Eric Xu^*, Ming-Wei Wang^*, Yi Jiang^*. Ligand recognition and G-protein coupling selectivity of cholecystokinin A receptor. Nat Chem Bio (2021);17(12): 1238-1244.

18. Shanshan Ma^#, Yan Chen^#, Antao Dai, Wanchao Yin, Jia Guo, Dehua Yang, Fulai Zhou, Yi Jiang, Ming-Wei Wang^*, H Eric Xu^*. Structural mechanism of calcium-mediated hormone recognition and Gβ interaction by the human melanocortin-1 receptor. Cell Research (2021);31(10): 1061-1071.

19. Yue Wang^#, Shimeng Guo^#, Youwen Zhuang^#, Ying Yun^#, Peiyu Xu^#, Xinheng He, Jia Guo, Wanchao Yin, H Eric Xu^*, Xin Xie^*, Yi Jiang^*. Molecular recognition of an acyl-peptide hormone and activation of ghrelin receptor. Nat Commun (2021);12(1): 5064.

20. Yu-Qi Ping ^#, Peng Xiao ^#, Fan Yang ^#, Ru-Jia Zhao ^#, Sheng-Chao Guo ^#, Xu Yan ^#, Xiang Wu ^#, Chao Zhang, Yan Lu, Fenghui Zhao, Fulai Zhou, Yue-Tong Xi, Wanchao Yin, Feng-Zhen Liu, Dong-Fang He, Dao-Lai Zhang, Zhong-Liang Zhu, Yi Jiang, Lutao Du, Shi-Qing Feng, Torsten Sch?neberg, Ines Liebscher^*, H Eric Xu^* & Jin-Peng Sun^*. Structural basis for the tethered peptide activation of adhesion GPCRs. Nature (2022); 604(7907):763-770.

21. Xiao-Dong Luan ^#, Bin-Xian Chen ^#, Wei-Juan Shang ^#, Wan-Chao Yin, Ye Jin, Lei-Ke Zhang ^#*, H Eric Xu ^#*, and Shu-Yang Zhang ^#*. Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376. Acta Pharmacologica Sinica (2022); 1-3.

22. Jia Duan ^#, Dan-Dan Shen ^#, Tingting Zhao ^#, Shimeng Guo ^#, Xinheng He, Wanchao Yin, Peiyu Xu, Yujie Ji, Li-Nan Chen, Jinyu Liu, Huibing Zhang, Qiufeng Liu, Yi Shi, Xi Cheng, Hualiang Jiang, H Eric Xu^*, Yan Zhang^*, Xin Xie^*, and Yi Jiang^*. Molecular basis for allosteric agonism and G protein subtype selectivity of galanin receptors. nature communications (2022); 13(1):1364.

23. Chongzhao You ^#, Yumu Zhang ^#, Peiyu Xu ^#, Sijie Huang, Wanchao Yin, H Eric Xu^*, and Yi Jiang^*. Structural insights into the peptide selectivity and activation of human neuromedin U receptors. nature communications (2022); 13(1):2045.

24. Xiao-Dong Luan ^#, Bin-Xian Chen ^#, Wei-Juan Shang ^#, Wan-Chao Yin, Ye Jin, Lei-Ke Zhang ^#, H Eric Xu ^#, Shu-Yang Zhang ^#. Author Correction: Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376. Acta Pharmacologica Sinica (2022); 1.

25. Can-rong Wu^*, Wan-chao Yin, Yi Jiang and H. Eric Xu^*. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Acta Pharmacologica Sinica (2022); 1-13.